Regenerative Medicine Reimbursement Models, Biotech-Academia Partnerships, & Bioart IP Disputes: Expert Insights for Stakeholder Success
WildExplorer5 In 2024, 70% of EU5 payers adopted risk-sharing MEAs for $1.5M+ regenerative therapies—here’s how payers, biotech firms, and academia can thrive in this $2B/year industry. Backed by the Alliance for…